Is Spyre Therapeutics, Inc. Common Stock a growth stock? A data-driven read on its earnings momentum, price leadership, and demand, scored against every US stock from SEC filings and daily prices, and re-ranked after every close.
Yes, SYRE fits the growth-stock profileAs of the 2026-07-27 close, SYRE scores 84 out of 99 on our growth-stock rating, a strong growth-stock profile. That ranks it 278th of 4,897 rated US stocks, the top 6% of the market.
Its strongest trait is L (leader or laggard) at 76, and its weakest is A (annual earnings growth) at 9. SYRE clears 4 of the six core growth traits we score per stock; the seventh, overall market direction, is judged market-wide.
On price, SYRE carries an elite Relative Strength rating of 98, meaning it has outperformed about 98% of the market over the past year.
Underneath the score: trading 3% below its 52-week high.
The six traits that separate real growth stocks from the rest: earnings, price leadership, and demand. Each is scored 1–99 against the whole US market. We compute them with the CANSLIM method, double-weighting earnings and relative strength.
| C | Current quarterly earnings most recent EPS growth vs. a year ago |
73 |
| A | Annual earnings growth multi-year earnings trend |
9 |
| N | New highs & catalysts proximity to new 52-week highs |
69 |
| S | Supply & demand volume behind the move vs. share supply |
30 |
| L | Leader or laggard Relative Strength within its group |
76 |
| I | Institutional sponsorship fund accumulation and 13F ownership |
62 |
SYRE shows the earnings strength and price leadership that define a growth stock. That is what our screen flags, not a recommendation to buy. Timing and market direction still matter.
The stocks ranking above SYRE today, the growth leaders you’d weigh against it.
Where SYRE sits in its base, its 52-week path, and the trait trend over the past year.
Every US stock scored on the traits that define a growth stock and re-ranked after each close, with the top ranks, the full trait breakdown, and today’s market read.
Open the app, free through September 1Yes, SYRE fits the growth-stock profile. SYRE shows the earnings strength and price leadership that define a growth stock. That is what our screen flags, not a recommendation to buy. Timing and market direction still matter.
Spyre Therapeutics, Inc. Common Stock (SYRE) scores 84 out of 99 on our growth-stock rating as of the 2026-07-27 close, ranking 278th of 4,897 rated US stocks.
We don't have current earnings-growth figures for SYRE.
SYRE has a Relative Strength rating of 98, meaning it has outperformed roughly 98% of the US market over the trailing year.
Create a free Growth Stock Analyzer account to see where SYRE ranks against every US stock, the stronger growth stocks to weigh against it, and its full price and earnings history.
Want the method behind the score? Read how we grade growth stocks with CANSLIM.